IMAGING OF THE POST-SURGICAL BREAST

Mariana Solari, MD
Assistant Professor of Radiology
Ragestein Breast Imaging Center
Rush University Medical Center

Objectives

- Describe imaging findings after oncologic, reconstructive and cosmetic breast surgery
- Understand benign post-surgical changes and differentiate them from recurrent breast carcinoma
- Review novel oncologic and reconstructive techniques
- Recognize imaging findings of BIA-ALCL

Breast Conservation Therapy (BCT)

- Treatment of choice for early stages of breast cancer
- Lumpectomy + Radiation Therapy
- Multiple trials have shown equivalent survival with BCT and MRM
- Local recurrence slightly higher with BCT
- +/- SLB and ALND.

Breast Conservation Therapy
Indications

- Size/location of tumor relative to breast size allows safe oncologic procedure and acceptable cosmetic result
- Locally advanced breast cancer with good result after neoadjuvant chemotherapy may become candidates for BCT

Breast Conservation Therapy
Contraindications

- Extensive multicentric disease
- Inability to obtain negative histologic margins despite reasonable attempts for re-excision.
- Unfavorable tumor-to-breast size ratio
- Inflammatory breast cancer.
- Contraindications to XRT: Previous RT, early pregnancy, Collagen vascular disease
- Risk reduction: patients with known BRCA genetic mutations

BCT- Imaging findings

- Skin thickening (>2mm) and trabecular thickening (>90% of patients)
- Overall increased breast density due to parenchymal edema/decreased compressibility
- Fluid collection/seroma: Seen in 50% of patients 1 month after surgery and 25% at 6 months
- Post-surgical AD: change in configuration in different projections, thick/curvilinear spiculations, central lucencies
- Post-surgical changes peak at 6-12 months and should progressively decrease until “new baseline” at years 2-3
- Any change such as increased density, skin thickening, new masses/calcifications should raise suspicion for recurrence

Chicago International Breast Course
The Westin Chicago River North
November 1-3, 2019


Palpable mass. History of BCT and BR

BCT and BR- Palpable mass
BCT - Calcifications

• **Dystrophic calcifications**: >5mm, irregular shape, central lucencies, no associated soft tissue mass or density, always at the site of surgery
• **Fat necrosis**: oval or round lucency with curvilinear, peripheral calcifications. Common complication after reconstructive surgery (breast reduction, myocutaneous flaps). May present as a palpable mass
• **Suture calcifications**: Suture material can also calcify with distinctive shapes

Mastectomy - Indications

• Contraindications for BCT
• Genetic susceptibility
• Patient preference
Mastectomy - Types

Modified Radical Mastectomy (MRM): removal of breast, skin, NAC, and level I and II axillary lymph nodes. Treatment of choice if no immediate reconstruction planned.

Skin-Sparing Mastectomy: complete removal of breast tissue and NAC, preserving the skin envelope and inframammary fold.

Nipple-Sparing Mastectomy: total skin-sparing mastectomy or Subcutaneous mastectomy: preserves skin and NAC. Optimal cosmetic outcome.

Novel Surgical Mastectomy Techniques: SSM and TSSM

- Oncologic safety versus improved cosmetic outcome
- Histologic review of skin flap in skin-sparing mastectomy: 59.5% residual breast tissue (TDLU's) and 9.5% residual carcinoma if flap > 5mm.
- Skin imaging findings of residual breast parenchyma should be reported by the radiologist as long-term imaging surveillance may be indicated.
- Pre-operative MRI necessary to determine eligibility: tumors less than 2 cm from the nipple or tumors size larger than 2 cm are the two predictors that have been associated with NAC involvement.

Reconstructive Surgery

- Post-mastectomy reconstruction options:
  - Synthetic implants.
  - Autologous tissue transfer (flaps): pedicle and free.
  - Autologous fat grafting.
**Autologous Fat Grafting**

- Lipoaspirate material injected to fill defects at lumpectomy sites or depressions along margins of reconstructed breast (U1Q) or for primary augmentation
- Imaging features: fat necrosis and oil cysts, in 75% patients
- Mammography: lucencies and calcifications
- Ultrasound: Cystic, echogenic or mixed echogenicity avascular masses
- MRI: hyperintensity on T1 non-fat-sat sequences, hypointensity on fat-sat sequences and T2 WI. Thin rim of enhancement on oil cysts

**Complications**

- Increase risk of infection
- Secondary malignancies: lung, secondary breast cancer, leukemias and radiation induced sarcoma
- Recurrent breast carcinoma
- Fat Necrosis

**Recurrent Breast Carcinoma**

Who is at increased risk?

- Incidence 1-2 % per year. Peaks at 2.5% between years 2-6
- Patients that did not receive XRT.
- Young patients: < 40 y/o.
- ER negative tumors.
- Lymphovascular invasion.
- Multifocal tumors.
- Close or positive margins.
- Extensive Intraductal Component: IDC + DCIS where the latter represents greater than 25% of tumor


**Recurrent Breast Carcinoma**

- New mass and/or calcifications
- Increasing architectural distortion/asymmetry/focal asymmetry
- Increase density of lumpectomy site
- Recurrent disease can take the form of invasive or in situ malignancy regardless of the original presentation and may not appear in a similar fashion than the primary cancer

Fat Necrosis vs Tumor Recurrence

- Risk of cancer recurrence low, therefore no imaging surveillance is necessary.
- Fat necrosis most common complication due to insufficient blood supply.
- TRAM flap: 58.5% of patients at average of 1.7 months after surgery.
- Cancer recurrence occurs in the skin envelope superficial to the autologous flap reconstruction and it is usually palpable.
- Posterior margin of the mastectomy bed not amenable to palpation. Pain & discomfort.
Fat Necrosis vs Recurrent Breast Carcinoma

FN vs. Recurrent Breast Carcinoma

DO NOT COPY
Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL)

- Non-Hodgkin lymphoma: abnormal T cell, CD30+ , ALK-
- Large, spontaneous periprosthetic fluid collection with unilateral breast enlargement (DDx: Infection, trauma)
- Palpable mass, lymphadenopathy, systemic symptoms
- Average 7-10 years after surgery (cosmetic or reconstructive)

*Only seen with textured surface implants* (no confirmed cases on smooth surface implants)

2019 NCCN Consensus Guidelines in Diagnosis and Treatment of BIA-ALCL

- Ultrasound: High S&S for detection of fluid and masses. Guidance for FNA
- MRI/PET
- FNA: at least 50cc
- Fluid analysis: Cytology, Immunohistochemistry and Flow Cytometry
- Core needle biopsy of masses and lymphadenopathy
- Confirmed cases should be reported to the PROFILE registry of the American Society of Plastic Surgery (www.thepsf.org/PROFILE)

• Excellent prognosis with early diagnosis and complete surgical excision

THANK YOU

mariana_solari@rush.edu